Pictured: AHA President and CEO Rick Pollack (left) and FAH President and CEO Chip Kahn briefed reporters this afternoon on findings from a new report on drug prices.

Continued rising drug prices, as well as shortages for many critical medications, are disrupting patient care and forcing hospitals to delay infrastructure and staffing investments and identify alternative therapies, according to a new report prepared by NORC at the University of Chicago for the AHA, Federation of American Hospitals and American Society of Health-System Pharmacists.
 
Updating and expanding on a 2016 report on rising inpatient drug costs to include outpatient drug costs and the impact of drug shortages, the study found that average total drug spending per hospital admission increased by 18.5 percent between fiscal years 2015 and 2017, including increases in some drug classes of more than 80 percent and exceeding the Medicare payment update by fivefold.
 
“This report confirms that we are in the midst of a prescription drug spending crisis that threatens patient access to care and hospitals’ and health systems’ ability to provide the highest quality of care,” said AHA President and CEO Rick Pollack on a telephone briefing with reporters. “Solutions must be worked on to rein in out-of-control drug prices and ease the drug shortages that are putting a strain on patient care.”
 
In addition, the AHA and others today released:

Related News Articles

Headline
The AHA today submitted comments on the revised version of the Lower Health Care Costs Act (S. 1895), legislation to prevent surprise medical bills, reduce…
Headline
Sens. Lamar Alexander, R-Tenn., and Patty Murray, D-Wash., today introduced the Lower Health Care Costs Act (S.1895), legislation to prevent surprise medical…
Headline
The House Committee on Oversight and Reform today held the third in a series of hearings examining solutions to the opioid epidemic, which focused on the…
Headline
The Senate Committee on Health, Education, Labor and Pensions today held a hearing on the Lower Health Care Costs Act, its draft legislation to prevent…
Headline
In an evaluation of 49 top-selling brand-name drugs, 28 of the drugs available since 2012 saw an increase in insurer and out-of-pocket costs of more than 50…
Headline
The Food and Drug Administration today published a notice seeking comment through July 30 on a potential change to the Opioid Analgesic Risk Evaluation and…